iPad app could screen entire UK population for Alzheimer’s symptomsHealth technology Medopad has announced a strategic collaboration with Johnson & Johnson’s pharma unit, Janssen, to research and Share XiPad app could screen entire UK population for Alzheimer’s symptomshttps://pharmaphorum.com/news/janssen-and-medopad-aim-to-use-ipad-tool-to-screen-uk-for-alzheimers/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
FDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell Share XFDA finally approves Sandoz’s Neulasta biosimilar, but will Amgen put up a fight?https://pharmaphorum.com/news/fda-finally-approves-sandozs-neulasta-biosimilar-but-will-amgen-put-up-a-fight/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Lilly and Boehringer rejig diabetes alliance as Jardiance soarsEli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on Share XLilly and Boehringer rejig diabetes alliance as Jardiance soarshttps://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
FDA slaps hold on Zolgensma trials as animal data raises safety questionThe FDA has placed a partial clinical hold on Novartis’ recently-approved gene therapy Zolgensma for spinal muscular atrophy Share XFDA slaps hold on Zolgensma trials as animal data raises safety questionhttps://pharmaphorum.com/news/fda-slaps-hold-on-zolgensma-trials-as-animal-data-raises-safety-question/
Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
